Skip to content

Sublingual Analgesia for Acute Abdominal Pain in Children

Sublingual Analgesia for Acute Abdominal Pain in Children. Ketorolac Versus Tramadol Versus Paracetamol, a Randomized, Control Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02465255
Enrollment
210
Registered
2015-06-08
Start date
2015-03-31
Completion date
2017-06-30
Last updated
2017-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Pain

Keywords

Acute Abdominal Pain, Sublingual Analgesia, Children, Ketorolac, Tramadol, Paracetamol, Analgesia

Brief summary

Acute abdominal pain is a frequent symptom in children admitted to the emergency department . In the past the fear of masking a surgical condition has justified withholding analgesia in patients with acute abdominal pain. By the 2000s, some clinical trials established that opioid analgesia before surgical consultation does not affect diagnostic accuracy or outcome in children with acute abdominal pain. Despite this, acute abdominal pain is still undertreated in this setting. Published paediatric trials studied the effect of opioid analgesia administered by parenteral route or by mouth. To the best of our knowledge no study investigated the effectiveness of sublingual analgesia. The purpose of this randomized controlled trial is to assess the effectiveness of three different drugs (ketorolac, tramadol, paracetamol), administered by the sublingual route, in children complaining of acute abdominal pain.

Interventions

DRUGKetorolac
DRUGTramadol
DRUGAcetaminophen

Sponsors

IRCCS Burlo Garofolo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Age 4 to 18 years * Emergency department admission for moderate to severe acute abdominal pain (VAS/NRS score \>=6) * Informed consent signed by parents or legal guardians

Exclusion criteria

* Known allergy or sensitivity to nonsteroidal anti-inflammatory drug, opioids or acetaminophen * Use of analgesic drugs in the 8 hours before * Clinical suspicion of abdominal pain due to fecal stasis * Moderate or severe dehydration (weight loss of more than 5%) * Known nephropathy, liver disease, metabolic or neurologic disease * Thrombocytopenia or history of bleeding disease

Design outcomes

Primary

MeasureTime frameDescription
Pain Score120 minutes after drug administrationPain score evaluated with visual analogical scale (VAS) or Numeric Rating Scale (NRS) depending on child age

Secondary

MeasureTime frameDescription
Pain Score30 minutes after drug administrationPain score evaluated with visual analogical scale (VAS) or Numeric Rating Scale (NRS) depending on child age
Missed or delayed diagnosis of acute appendicitis or other abdominal pathology (i.e., pancreatitis)24 hours after drug administration
Adverse eventsup to 180 hours after the drug administrationPresence of nausea, vomiting, diarrhea, headache, hyper- or hypotension, decreased excretion of urine, bleeding

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026